243 related articles for article (PubMed ID: 28837356)
1. Phenotypic Assays for Characterizing Compound Effects on Induced Pluripotent Stem Cell-Derived Cardiac Spheroids.
Sirenko O; Hancock MK; Crittenden C; Hammer M; Keating S; Carlson CB; Chandy G
Assay Drug Dev Technol; 2017; 15(6):280-296. PubMed ID: 28837356
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic Characterization of Toxic Compound Effects on Liver Spheroids Derived from iPSC Using Confocal Imaging and Three-Dimensional Image Analysis.
Sirenko O; Hancock MK; Hesley J; Hong D; Cohen A; Gentry J; Carlson CB; Mann DA
Assay Drug Dev Technol; 2016 Sep; 14(7):381-94. PubMed ID: 27494736
[TBL] [Abstract][Full Text] [Related]
3. Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.
Sirenko O; Cromwell EF; Crittenden C; Wignall JA; Wright FA; Rusyn I
Toxicol Appl Pharmacol; 2013 Dec; 273(3):500-7. PubMed ID: 24095675
[TBL] [Abstract][Full Text] [Related]
4. High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds.
Lu HR; Whittaker R; Price JH; Vega R; Pfeiffer ER; Cerignoli F; Towart R; Gallacher DJ
Toxicol Sci; 2015 Dec; 148(2):503-16. PubMed ID: 26358003
[TBL] [Abstract][Full Text] [Related]
5. A Scalable Approach Reveals Functional Responses of iPSC Cardiomyocyte 3D Spheroids.
Burnham MP; Harvey R; Sargeant R; Fertig N; Haddrick M
SLAS Discov; 2021 Mar; 26(3):352-363. PubMed ID: 33283596
[TBL] [Abstract][Full Text] [Related]
6. Development and Characterization of a Scaffold-Free 3D Spheroid Model of Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes.
Beauchamp P; Moritz W; Kelm JM; Ullrich ND; Agarkova I; Anson BD; Suter TM; Zuppinger C
Tissue Eng Part C Methods; 2015 Aug; 21(8):852-61. PubMed ID: 25654582
[TBL] [Abstract][Full Text] [Related]
7. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
[TBL] [Abstract][Full Text] [Related]
8. High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes.
Grimm FA; Iwata Y; Sirenko O; Bittner M; Rusyn I
Assay Drug Dev Technol; 2015 Nov; 13(9):529-46. PubMed ID: 26539751
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
Himmel HM
J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
[TBL] [Abstract][Full Text] [Related]
10. Human Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells in Phenotypic Screening: A Transforming Growth Factor-β Type 1 Receptor Kinase Inhibitor Induces Efficient Cardiac Differentiation.
Drowley L; Koonce C; Peel S; Jonebring A; Plowright AT; Kattman SJ; Andersson H; Anson B; Swanson BJ; Wang QD; Brolen G
Stem Cells Transl Med; 2016 Feb; 5(2):164-74. PubMed ID: 26683871
[TBL] [Abstract][Full Text] [Related]
11. High-content assays for characterizing the viability and morphology of 3D cancer spheroid cultures.
Sirenko O; Mitlo T; Hesley J; Luke S; Owens W; Cromwell EF
Assay Drug Dev Technol; 2015 Sep; 13(7):402-14. PubMed ID: 26317884
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of cardiotoxicity assessment using calcium transient in human induced pluripotent stem cell-derived cardiomyocytes.
Watanabe H; Honda Y; Deguchi J; Yamada T; Bando K
J Toxicol Sci; 2017; 42(4):519-527. PubMed ID: 28717111
[TBL] [Abstract][Full Text] [Related]
13. Assessment of extracellular field potential and Ca
Abi-Gerges N; Pointon A; Oldman KL; Brown MR; Pilling MA; Sefton CE; Garside H; Pollard CE
J Pharmacol Toxicol Methods; 2017; 83():1-15. PubMed ID: 27622857
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
[TBL] [Abstract][Full Text] [Related]
15. High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes.
Bedut S; Seminatore-Nole C; Lamamy V; Caignard S; Boutin JA; Nosjean O; Stephan JP; Coge F
Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H44-53. PubMed ID: 27199128
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic screening with human iPS cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy.
Carlson C; Koonce C; Aoyama N; Einhorn S; Fiene S; Thompson A; Swanson B; Anson B; Kattman S
J Biomol Screen; 2013 Dec; 18(10):1203-11. PubMed ID: 24071917
[TBL] [Abstract][Full Text] [Related]
17. Measurement of Contractility and Calcium Release in Cardiac Spheroids.
Zuppinger C
Methods Mol Biol; 2019; 1929():41-52. PubMed ID: 30710266
[TBL] [Abstract][Full Text] [Related]
18. Engineering a functional three-dimensional human cardiac tissue model for drug toxicity screening.
Lu HF; Leong MF; Lim TC; Chua YP; Lim JK; Du C; Wan ACA
Biofabrication; 2017 May; 9(2):025011. PubMed ID: 28393762
[TBL] [Abstract][Full Text] [Related]
19. Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes.
Matsui T; Miyamoto K; Yamanaka K; Okai Y; Kaushik EP; Harada K; Wagoner M; Shinozawa T
Toxicol Appl Pharmacol; 2019 Nov; 383():114761. PubMed ID: 31533062
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury.
Bell CC; Lauschke VM; Vorrink SU; Palmgren H; Duffin R; Andersson TB; Ingelman-Sundberg M
Drug Metab Dispos; 2017 Apr; 45(4):419-429. PubMed ID: 28137721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
